|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
WO1986005779A1
(en)
|
1985-04-03 |
1986-10-09 |
Yamanouchi Pharmaceutical Co., Ltd. |
Phenylene derivatives
|
|
US5273986A
(en)
|
1992-07-02 |
1993-12-28 |
Hoffmann-La Roche Inc. |
Cycloalkylthiazoles
|
|
WO2002062792A1
(en)
|
2001-02-02 |
2002-08-15 |
Takeda Chemical Industries, Ltd. |
Jnk inhibitor
|
|
DE60334303D1
(de)
|
2002-07-03 |
2010-11-04 |
Tasuku Honjo |
Immunpotenzierende zusammensetzungen
|
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
|
US7563869B2
(en)
|
2003-01-23 |
2009-07-21 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human PD-1
|
|
WO2004099388A2
(en)
|
2003-03-05 |
2004-11-18 |
Proteologics, Inc. |
Cbl-b polypeptides, complexes and related methods
|
|
US7320992B2
(en)
|
2003-08-25 |
2008-01-22 |
Amgen Inc. |
Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
|
|
US7326732B2
(en)
|
2004-02-12 |
2008-02-05 |
Pharmagene Laboratories Limited |
EP2 receptor agonists
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
WO2007072225A2
(en)
|
2005-12-01 |
2007-06-28 |
Medical Prognosis Institute |
Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
|
|
WO2008033403A2
(en)
|
2006-09-13 |
2008-03-20 |
The Trustees Of Columbia University In The City Of New York |
Agents and methods to elicit anti-tumor immune response
|
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
|
AT506041A1
(de)
|
2007-12-10 |
2009-05-15 |
Univ Innsbruck |
Verfahren zur erhöhung der immunreaktivität
|
|
ES2420846T3
(es)
|
2008-02-05 |
2013-08-27 |
F. Hoffmann-La Roche Ag |
Nuevas piridinonas y piridazinonas
|
|
PT2242773T
(pt)
|
2008-02-11 |
2017-09-15 |
Cure Tech Ltd |
Anticorpos monoclonais para o tratamento de tumores
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
WO2010036959A2
(en)
|
2008-09-26 |
2010-04-01 |
Dana-Farber Cancer Institute |
Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
WO2011076725A1
(en)
|
2009-12-21 |
2011-06-30 |
Bayer Cropscience Ag |
Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi
|
|
CA3034600C
(en)
|
2010-05-07 |
2020-11-10 |
Genentech, Inc. |
Pyridone and aza-pyridone compounds and methods of use
|
|
AR082590A1
(es)
|
2010-08-12 |
2012-12-19 |
Hoffmann La Roche |
Inhibidores de la tirosina-quinasa de bruton
|
|
EP2471548A1
(de)
|
2010-12-28 |
2012-07-04 |
Apeiron Biologics AG |
siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs
|
|
AR086992A1
(es)
|
2011-06-20 |
2014-02-05 |
Bayer Ip Gmbh |
Tienilpiri(mi)dinilpirazoles
|
|
BR112014002353B1
(pt)
|
2011-08-01 |
2022-09-27 |
Genentech, Inc |
Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
|
|
US20130110678A1
(en)
|
2011-11-02 |
2013-05-02 |
Apple Inc. |
Purchasing a product in a store using a mobile device
|
|
UA111756C2
(uk)
|
2011-11-03 |
2016-06-10 |
Ф. Хоффманн-Ля Рош Аг |
Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
|
|
US8669251B2
(en)
|
2011-11-03 |
2014-03-11 |
Genentech, Inc. |
8-fluorophthalazin-1(2H)-one compounds
|
|
KR102438072B1
(ko)
|
2012-01-12 |
2022-08-31 |
예일 유니버시티 |
E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
|
|
US9499548B2
(en)
|
2012-09-13 |
2016-11-22 |
Hoffmann-La Roche Inc. |
Inhibitors of bruton's tyrosine kinase
|
|
US10308707B2
(en)
|
2013-12-02 |
2019-06-04 |
Aaron Diamond Aids Research Center |
Bispecific HIV-1-neutralizing antibodies
|
|
AU2014360446A1
(en)
|
2013-12-05 |
2016-06-09 |
Pharmacyclics, Llc |
Inhibitors of Bruton's tyrosine kinase
|
|
EP3218409A2
(en)
|
2014-11-11 |
2017-09-20 |
Sutro Biopharma, Inc. |
Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
|
|
BR112017025986A2
(pt)
|
2015-06-02 |
2018-08-14 |
Pharmacyclics Llc |
inibidores de tirosina quinase de bruton.
|
|
CN108026088B
(zh)
|
2015-07-17 |
2021-02-12 |
武田药品工业株式会社 |
用作hdac抑制剂的噁二唑衍生物
|
|
EP3254701A1
(en)
|
2016-06-09 |
2017-12-13 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Cbl-b inhibitor comprising a cbl-b binding peptide for the prevention or treatment of fungal infections
|
|
US10842878B2
(en)
|
2016-11-22 |
2020-11-24 |
Dana-Farber Cancer Institute, Inc. |
Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
|
|
EP3585813A1
(en)
|
2017-02-22 |
2020-01-01 |
Sutro Biopharma, Inc. |
Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same
|
|
EP3630291B9
(en)
|
2017-05-26 |
2024-05-29 |
Cancer Research Technology Limited |
Benzimidazolone derived inhibitors of bcl6
|
|
WO2019063748A1
(en)
|
2017-09-30 |
2019-04-04 |
Glaxosmithkline Intellectual Property Development Limited |
INHIBITORS OF ROR-GAMMA
|
|
EP3743063A4
(en)
|
2018-01-26 |
2021-10-20 |
Nurix Therapeutics, Inc. |
CBL-B INHIBITORS AND THEIR METHODS OF USE
|
|
EP3867242A1
(en)
|
2018-10-15 |
2021-08-25 |
Nurix Therapeutics, Inc. |
Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
|
|
EP3924350A1
(en)
|
2019-02-13 |
2021-12-22 |
Nurix Therapeutics, Inc. |
Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
|
|
KR102922115B1
(ko)
|
2019-04-09 |
2026-02-04 |
누릭스 테라퓨틱스 인코포레이티드 |
Cbl-b 억제용의 3-치환된 피페리딘 화합물, 및 암 백신 및/또는 종양용해 바이러스와 조합된 cbl-b 억제제의 용도
|
|
CA3140873A1
(en)
|
2019-05-17 |
2020-11-26 |
Nurix Therapeutics, Inc. |
Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof
|
|
CA3294689A1
(en)
|
2019-06-26 |
2026-03-02 |
Nurix Therapeutics, Inc. |
Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof
|
|
US11438877B2
(en)
|
2019-06-27 |
2022-09-06 |
Qualcomm Incorporated |
Signaling for sidelink beam operation
|
|
US12653809B2
(en)
|
2019-07-30 |
2026-06-16 |
Nurix Therapeutics, Inc. |
Urea, amide, and substituted heteroaryl compounds for CBL-B inhibition
|
|
EP4034141A1
(en)
|
2019-09-24 |
2022-08-03 |
Nurix Therapeutics, Inc. |
Cbl inhibitors and compositions for expansion of immune cells
|
|
WO2021091575A1
(en)
|
2019-11-08 |
2021-05-14 |
Nurix Therapeutics, Inc. |
Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
|
|
CA3160713A1
(en)
|
2019-12-04 |
2021-06-10 |
Nurix Therapeutics, Inc. |
Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
|
|
JP6774133B1
(ja)
|
2020-04-01 |
2020-10-21 |
株式会社アサヌマホールディングス |
メンバースコープを用いて参加者の相互作用を制御するイベント管理システム
|
|
US12016860B2
(en)
|
2021-04-08 |
2024-06-25 |
Nurix Therapeutics, Inc. |
Combination therapies with Cbl-b inhibitor compounds
|
|
MX2024002189A
(es)
|
2021-08-20 |
2024-06-11 |
Biomea Fusion Inc |
Forma cristalina de n-[4-[4-(4-morfolinil)-7h-pirrolo[2,3-d]pirimi din-6-il]fenil]-4-[[3(r)-[(1-oxo)-2-propen-1-il)amino]-1-piperidi nil]metil]-2-piridinacarboxamida, un inhibidor irreversible de menina-mll para el tratamiento del cancer.
|
|
WO2023205180A1
(en)
|
2022-04-19 |
2023-10-26 |
Nurix Therapeutics, Inc. |
Biomarkers for cbl, and compositions and methods for their use
|
|
WO2023250097A1
(en)
|
2022-06-22 |
2023-12-28 |
Nurix Therapeutics, Inc. |
Combination therapies with cbl-b inhibitor compounds and antiemetic agents
|